

Maria Lia Scribano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8062043/publications.pdf>

Version: 2024-02-01

48
papers

3,527
citations

304743
22
h-index

223800
46
g-index

49
all docs

49
docs citations

49
times ranked

4102
citing authors

#	ARTICLE	IF	CITATIONS
1	Female reproductive health and inflammatory bowel disease: A practice-based review. Digestive and Liver Disease, 2022, 54, 19-29.	0.9	16
2	Incident Colorectal Cancer in Inflammatory Bowel Disease. Cancers, 2022, 14, 721.	3.7	5
3	Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110724.	3.2	14
4	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.9	22
5	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IG-IBD LIVE</scp> study. Alimentary Pharmacology and Therapeutics, 2022, 56, 95-109.	3.7	25
6	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterology Journal, 2021, 9, 507-516.	3.8	11
7	Vitamin D Signaling in Gastro-Rheumatology: From Immuno-Modulation to Potential Clinical Applications. International Journal of Molecular Sciences, 2021, 22, 2456.	4.1	4
8	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Digestive and Liver Disease, 2021, , .	0.9	2
9	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Alimentary Pharmacology and Therapeutics, 2021, 54, 1432-1441.	3.7	11
10	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmunity Reviews, 2020, 19, 102457.	5.8	18
11	Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?. Digestive Diseases and Sciences, 2020, 66, 2855-2864.	2.3	9
12	Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opinion on Biological Therapy, 2020, 20, 1321-1329.	3.1	11
13	Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. Digestive and Liver Disease, 2019, 51, 346-351.	0.9	5
14	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflammatory Bowel Diseases, 2019, 26, 450-459.	1.9	33
15	Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet, The, 2019, 393, 1699-1707.	13.7	155
16	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
17	Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2019, 10, 47.	3.5	14
18	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. Digestive and Liver Disease, 2019, 51, 640-647.	0.9	14

#	ARTICLE	IF	CITATIONS
19	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.9	22
20	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World Journal of Gastroenterology, 2018, 24, 2457-2467.	3.3	61
21	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterology Research and Practice, 2018, 2018, 1-7.	1.5	7
22	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.9	42
23	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	1.3	30
24	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.9	34
25	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	12.1	91
26	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	27.0	366
27	Role of Rifaximin in Inflammatory Bowel Disease Treatment. Mini-Reviews in Medicinal Chemistry, 2015, 16, 225-229.	2.4	3
28	Budesonide multi-matrix system formulation for treating ulcerative colitis. Expert Opinion on Pharmacotherapy, 2014, 15, 741-743.	1.8	6
29	Mucosal Healing With Thalidomide in Refractory Crohn's Disease Patients Intolerant of Anti-TNF- α Drugs. Journal of Clinical Gastroenterology, 2014, 48, 530-533.	2.2	15
30	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's and Colitis, 2014, 8, 1217-1221.	1.3	53
31	Antibiotics and Inflammatory Bowel Diseases. Digestive Diseases, 2013, 31, 379-384.	1.9	24
32	Use of antibiotics in the treatment of Crohn's disease. World Journal of Gastroenterology, 2013, 19, 648.	3.3	28
33	Rifaximin and Crohn's disease. World Journal of Gastroenterology, 2013, 19, 7487.	3.3	0
34	Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. Gastroenterology, 2012, 142, 473-481.e4.	1.3	165
35	Randomized Controlled Trials in Steroid Dependent and in Severe Colitis. Reviews on Recent Clinical Trials, 2012, 7, 314-320.	0.8	0
36	Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Current Opinion in Gastroenterology, 2009, 25, 329-333.	2.3	42

#	ARTICLE	IF	CITATIONS
37	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1168-1170.	1.9	21
38	Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1117-1125.	3.7	189
39	Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with <i>Lactobacillus GG</i> . <i>Gut</i> , 2002, 51, 405-409.	12.1	492
40	Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission. <i>American Journal of Gastroenterology</i> , 2000, 95, 1213-1220.	0.4	363
41	Treatment of Esophageal Crohn's Disease by Enteral Feeding via Percutaneous Endoscopic Gastrostomy. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 176-179.	2.6	12
42	Antibiotic Use in Crohn's Disease. <i>BioDrugs</i> , 1997, 8, 293-306.	4.6	14
43	Mortality among patients with ulcerative colitis: Rome 1970-1989. <i>European Journal of Epidemiology</i> , 1997, 13, 189-194.	5.7	23
44	Long-term symptom patterns in duodenal ulcer: Psychosocial factors. <i>Journal of Psychosomatic Research</i> , 1996, 41, 465-472.	2.6	23
45	Psychologic Predictors of Duodenal Ulcer Healing. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 84-89.	2.2	30
46	Patterns of Biologic and Psychologic Risk Factors in Duodenal Ulcer Patients. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 110-117.	2.2	36
47	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. <i>Gastroenterology</i> , 1995, 108, 345-349.	1.3	197
48	Development of the perceived stress questionnaire: A new tool for psychosomatic research. <i>Journal of Psychosomatic Research</i> , 1993, 37, 19-32.	2.6	731